

1-1-2019

Vitamin B-12 deficiency in type 2 diabetic patients on metformin: a cross-sectional study from South-Western part of Ghana

Maryam Yakubu

Edwin Ferguson Laing

Paul Nsiah

Richard Anthony

Emmanuel Acheampong
Edith Cowan University

See next page for additional authors

Follow this and additional works at: <https://ro.ecu.edu.au/ecuworkspost2013>



Part of the [Medicine and Health Sciences Commons](#)

[10.1080/20905068.2019.1662647](https://doi.org/10.1080/20905068.2019.1662647)

Yakubu, M., Laing, E. F., Nsiah, P., Anthony, R., Acheampong, E., Asamoah, S. K., ... & Owiredi, E. W. (2019). Vitamin B12 deficiency in type 2 diabetic patients on metformin: a cross-sectional study from South-Western part of Ghana. *Alexandria Journal of Medicine*, 55(1), 58-67.

<https://doi.org/10.1080/20905068.2019.1662647>

This Journal Article is posted at Research Online.

<https://ro.ecu.edu.au/ecuworkspost2013/8271>

Authors

Maryam Yakubu, Edwin Ferguson Laing, Paul Nsiah, Richard Anthony, Emmanuel Acheampong, Samuel Kojo Asamoah, Enoch Odame Anto, Gabriel Djokoto, Evans Adu Asamoah, and Eddie-Williams Owiredo



Vitamin B₁₂ deficiency in type 2 diabetic patients on metformin: a cross-sectional study from South-Western part of Ghana

Maryam Yakubu, Edwin Ferguson Laing, Paul Nsiah, Richard Anthony, Emmanuel Acheampong, Samuel Kojo Asamoah, Enoch Odame Anto, Gabriel Djokoto, Evans Adu Asamoah & Eddie-Williams Owiredu

To cite this article: Maryam Yakubu, Edwin Ferguson Laing, Paul Nsiah, Richard Anthony, Emmanuel Acheampong, Samuel Kojo Asamoah, Enoch Odame Anto, Gabriel Djokoto, Evans Adu Asamoah & Eddie-Williams Owiredu (2019) Vitamin B₁₂ deficiency in type 2 diabetic patients on metformin: a cross-sectional study from South-Western part of Ghana, Alexandria Journal of Medicine, 55:1, 58-67, DOI: [10.1080/20905068.2019.1662647](https://doi.org/10.1080/20905068.2019.1662647)

To link to this article: <https://doi.org/10.1080/20905068.2019.1662647>



© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 12 Sep 2019.



[Submit your article to this journal](#)



Article views: 1298



[View related articles](#)



[View Crossmark data](#)

Vitamin B₁₂ deficiency in type 2 diabetic patients on metformin: a cross-sectional study from South-Western part of Ghana

Maryam Yakubu^{a,b}, Edwin Ferguson Laing^a, Paul Nsiah^c, Richard Anthony^d, Emmanuel Acheampong^{a,e}, Samuel Kojo Asamoah^b, Enoch Odame Anto^{a,e}, Gabriel Djokoto^b, Evans Adu Asamoah^b and Eddie-Williams Owiredu^b

^aDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; ^bLaboratory Department, Effia-Nkwanta Regional Hospital, Western Region, Ghana; ^cChemical Pathology Department, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana; ^dDepartment of Medicine, Effia-Nkwanta Regional Hospital, Western Region, Ghana; ^eSchool of Medical and Health Sciences, Edith Cowan University, Perth, Australia

ABSTRACT

Introduction: Metformin is the most widely administered anti-diabetic medication among type 2 diabetes mellitus (T2DM) patients. However, metformin induces vitamin B₁₂ malabsorption which may increase the risk of vitamin B₁₂ deficiency among T2DM patients. We determined the prevalence of vitamin B₁₂ deficiency and related risk factors among Ghanaian T2DM patients on metformin therapy.

Methods: This cross-sectional study recruited 196 T2DM patients attending the outpatient diabetic clinic at the Effia Nkwanta Regional Hospital, Ghana. Fasting venous blood was collected for biochemical analysis. Vitamin B₁₂ deficiency was defined as serum B₁₂ <100 pg/ml and methylmalonic acid (MMA) ≥ 0.4 μmol/L.

Results: The prevalence of vitamin B₁₂ deficiency based on serum vitamin B₁₂, MMA, and the combination of both methods were 32.1%, 14.8%, and 14.3%, respectively. Longer duration of metformin use [5–9 years; aOR= 2.83, 95% CI (1.03–7.81), p=0.045 and ≥10 years; aOR= 4.17, 95% CI (1.41–12.33), p=0.010], higher daily dose of metformin [1000–2000 mg/day; aOR= 1.34, 95% CI (0.25–2.74), p=0.038 and >2000 mg/day; aOR= 1.13, 95% CI (0.39–2.97), p=0.047], and very high body fat [aOR= 2.98, 95% CI (1.47–6.05), p=0.020] were significantly associated with increased odds of vitamin B₁₂ deficiency. For daily dose of metformin, a cutoff value of 1500 mg/day presented with a sensitivity, specificity, and AUC of 71.4%, 40.1%, and 0.54 (95% CI, 0.53–0.54), respectively, in predicting vitamin B₁₂ deficiency. A ≥ six (6) years duration of metformin therapy presented with a sensitivity, specificity, and AUC of 70.4%, 62.9%, and 0.66 (95% CI, 0.57–0.75), respectively, in predicting vitamin B₁₂ deficiency.

Conclusion: Vitamin B₁₂ deficiency is high among T2DM patients on metformin therapy in Ghana. There is the need for regular monitoring of vitamin B₁₂ levels especially in T2DM patients on metformin daily dose of ≥ 1500 mg for duration of therapy ≥ 6 years.

ARTICLE HISTORY

Received 13 May 2019
Accepted 17 August 2019

KEYWORDS

Type 2 diabetes mellitus; metformin; vitamin B₁₂ deficiency; methylmalonic acid

1. Introduction

Diabetes mellitus (DM) is a pervasive chronic metabolic disorder and accounts for up to 90% of all diagnosed diabetes [1,2]. Type 2 diabetes mellitus (T2DM) is the most common form of DM, accounting for approximately 90% of DM cases [3]. In Ghana, 6.3% and 6.4% have been quoted as crude and age-adjusted prevalence of T2DM [4,5]. T2DM is associated with several detrimental microvascular and macrovascular complications [6]. As such, effective management of the disease is crucial.

The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend metformin as the first therapeutic choice for T2DM management with concurrent lifestyle modifications. Reports indicated that metformin improves peripheral insulin sensitivity and reduces the risk of cardiovascular mortality in T2DM [7,8] in

addition to its beneficial effects on weight loss and vascular protection [9]. Nonetheless, as with most medications, the use of metformin present with some side effects. Though most of these side effects are mild, reports indicate that metformin use is associated with the diminution of the terminal iliac uptake of vitamin B₁₂ [10,11]. Other studies also report that long-term use of metformin results in vitamin B₁₂ malabsorption, with a concomitant reduction in serum vitamin B₁₂ levels [11–13]. Metformin-induced Vitamin B₁₂ deficiency has been reported to be duration of therapy- and dose-dependent [12].

Metformin-induced vitamin B₁₂ deficiency has also been associated with neuropathy. The neuropathy associated with vitamin B₁₂ deficiency ranges from paresthesia and attenuated peripheral sensation in response to changes in mental status and proprioception [7] which overlap with diabetic neuropathy. The progression of vitamin B₁₂ deficiency-induced neurologic damage can,

however, be abated through early detection and vitamin B₁₂ therapy [14]. Nonetheless, if peripheral neuropathy due to deficiency of vitamin B₁₂ is misconstrued as diabetic peripheral neuropathy, permanent neurological damage may occur [15].

Despite the growing evidence of metformin-induced vitamin B₁₂ deficiency, the prevalence and association between metformin use and vitamin B₁₂ deficiency in the Ghanaian population is yet to be elucidated. Furthermore, there are no guidelines to address how often Ghanaian T2DM patients on metformin should be screened for the risk of vitamin B₁₂ deficiency which would inform appropriate prescription of vitamin B₁₂ supplements probably due to limited studies on the subject matter.

Diagnosis of vitamin B₁₂ deficiency can, however, be difficult. Reports indicate that high serum vitamin B₁₂ levels can be accompanied by signs of deficiency, and functional deficiency from tissue uptake defects and action of vitamin B₁₂ at the cellular level have been implicated in this association [16,17]. Thus, functional vitamin B₁₂ deficiency can occur regardless elevated serum B₁₂ levels [17]. As such, a more sensitive screening method is warranted. One such method exploits metabolites that accumulate due to vitamin B₁₂ deficiency. Vitamin B₁₂ is involved in the conversion of methylmalonic acid (MMA) to succinyl-CoA as well as homocysteine (HC) to methionine in combination with folic acid [18]. Serum vitamin B₁₂, in combination with MMA levels, have been demonstrated to be effective in classifying vitamin B₁₂ deficiency compared to serum vitamin B₁₂ alone [16,19].

This study, therefore, employed both serum vitamin B₁₂ and MMA levels to estimate the prevalence of vitamin B₁₂ deficiency and identify risk factors associated with vitamin B₁₂ deficiency among Ghanaian T2DM patients.

2. Materials and methods

2.1. Study design / setting

This cross-sectional study was conducted at the Diabetic clinic of the Effia Nkwanta Regional Hospital, Takoradi, Ghana. Effia Nkwanta Hospital is a referral center for peripheral health facilities in the Western Region. The diabetic clinic offers general and specialized care for diabetes patients.

2.2. Ethical consideration

The study protocol was reviewed and approved by the Committee for Human Research, Publications and Ethics of SMS/KNUST/KATH and institutional approval was obtained from Effia Nkwanta Regional Hospital. Written informed consent was obtained from participants after the objectives and benefits of

the study were explained to them. Participation was entirely voluntary and strict confidentiality of participants' information was maintained throughout the study.

2.3. Study population

The sample size for this study was calculated using the Raosoft sample size calculator [20]. At 95% confidence level, 7% margin of error, and a response distribution of 50%, the minimum sample size for the study was 180 T2DM patients. In an effort to enhance the statistical power of the study, a total of 250 T2DM patients were targeted for the study. However, upon excluding subjects who did not fulfill the inclusion criteria, a total of 196 participants were enrolled in the study. Non-probability sampling technique was employed to recruit 196 consecutive consenting participants who were already diagnosed of T2DM and on treatment. Subjects recruitment occurred during patients' routine clinic visit. Since T2DM is considered a disease of the aged, patients aged 35–65 years old, who had been on metformin, with minimum daily dose of 500 mg, for at least 6 months were included. T2DM patients who were pregnant/lactating, alcoholics or drug abuse, known cases of malabsorption (gastrointestinal surgery, inflammatory bowel diseases and gluten allergy), chronic kidney disease, pernicious anemia, thalassaemia, sickle cell anemia, consumption of vitamin B₁₂ or calcium supplementation during the last 3 months and receiving antibiotics or any medications known to influence gastrointestinal motility were excluded from the study. All relevant clinical data were retrieved from the hospital's archive. Participants' selection protocol is shown in Figure 1.

2.4. Questionnaire administration

Validated questionnaire was used for data collection. The questionnaire gathered information on demographic characteristics, anthropometric variables, medications (type, dose, and duration) and symptoms of neuropathy. Patients information from the hospital's archive were cross-referenced to confirm responses such as medication dose, duration of use, and duration of diabetes.

2.5. Blood pressure and anthropometric measurements

Blood pressure was measured from the left upper arm using a mercury sphygmomanometer and a stethoscope by a trained nurse at the diabetic clinic. Participants were asked to rest for at least 5 min before measurement. The average of the two readings taken 5 min apart was recorded as the blood pressure measurement.




Figure 1. Flowchart of the protocol for the selection of subject.

Height was measured without wearing shoes using a wall-mounted ruler, to the nearest 0.1 m. Waist and hip circumferences were measured to nearest centimeter using a measuring tape. Waist to hip ratio (WHR) = WC (m)/HC (m), waist to height ratio and (WHtR) = WC (m)/height (m) were calculated [21]. Total body fat, percentage visceral fat (VF) and skeletal muscle were also estimated using the Omron Body Composition Monitor (Omron Corporation, Japan). Body mass index (BMI) was calculated using the equation; $[BMI (kg/m^2) = weight/height^2]$ [22].

2.6. Sample collection, preparation and biochemical assays

Five milliliters (5 ml) of venous blood sample was collected after an overnight fast. One (1) milliliter of blood was dispensed into tubes containing fluoride oxalate, another 1 ml was dispensed into tubes containing EDTA, and the remaining 3 ml of blood was dispensed into gel separator tubes. The sample in the EDTA tube was used for estimation of hemoglobin (Hb) and glycated hemoglobin (HbA1c) while the sample in the fluoride oxalate was used for glucose estimation (FPS). The gel separator tubes were placed in a centrifuge and spun at 3000 rpm for 5 min to obtain the serum. Hb, HbA1c, and FPS were measured immediately and the serum for the measurement of other biochemical variables were stored at $-20^{\circ}C$ until analysis. FPS, HbA1c, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and calcium were estimated using an automated chemistry analyzer (Selectra Pro S System, Elitech Group, France). The estimation of serum vitamin B₁₂ was based on solid-phase Enzyme Linked Immunosorbent Assay (ELISA) method (standardized with an intra-assay %CVs = 4.4–5.6% and inter-assay

%CVs = 6.6–7.9%) (MyBioSource, Inc. San Diego, CA, USA) according to the manufacturer's instructions. Briefly, 100 μ L of standards, samples and controls were pipetted into appropriate microtitre wells followed by 100 μ L of enzyme conjugate reagent, mixed thoroughly, covered with an adhesive strip, and incubated at $37^{\circ}C$ for 60 min. The incubation mixture was aspirated from the wells followed by five washes with the wash solution (400 μ L). Residual water droplets were removed by striking the wells onto absorbent paper. A 50 μ L of Substrate A and 50 μ L of Substrate B were pipetted into each well, mixed gently and incubated at $37^{\circ}C$ for 15 min.

The estimation of serum methylmalonic acid was based on the competitive binding enzyme immunoassay technique (standardized with an intra-assay %CVs <6.1% and inter-assay %CVs <10.2%) (MyBioSource, Inc. San Diego, CA, USA) according to the manufacturer's instructions. Briefly, 50 μ L of standards, controls, and samples were pipetted into appropriate microtitre wells which were pre-coated with an antibody specific to MMA. Fifty microliters (50 μ L) of Detection A working solution was added to each well, mixed thoroughly, covered with an adhesive strip, and incubated at $37^{\circ}C$ for 60 min. The incubation mixture was aspirated from the wells followed by five washes with the wash solution (400 μ L). Residual water droplets were removed by striking the wells onto absorbent paper. A 100 μ L of Detection A working solution was pipetted into each well, mixed gently and incubated at $37^{\circ}C$ for 45 min.

Both reactions were stopped by adding 50 μ L of Stop Solution to each well and gently mixed for 30 s. The absorbance of the final colored product was measured spectrophotometrically at 450 nm using Thermo Electron Multiskan EX plate reader (Shanghai, China). The mean absorbance value (OD_{450}) for each set of reference standards, controls

and samples were calculated. The calculated mean OD₄₅₀ obtained for each reference standard were used to construct a standard curve and the concentrations of samples and controls determined from the standard curve. Vitamin B₁₂ deficiency was defined by B₁₂ levels <100 pg/mL based on measurement of serum vitamin B₁₂ and ≥ 0.4 μ mol/L based on MMA levels [23,24]. Daily calibration and maintenance of analyzer was performed according to the manufacturer's instructions as previously described [25]. Quality control (QC) was assessed using quality control materials provided by the manufacturer.

2.7. Statistical analysis

Categorical data were presented as frequencies and percentages, and Chi-square and Fisher exact test were used to test for significance of associations where applicable. Parametric and non-parametric continuous data were presented as means \pm SD and medians (IQR), respectively, and Independent t-test and Mann Whitney U test were used to test significance of associations where applicable. Multivariate logistic regression model was used to identify risk factors associated with vitamin B₁₂ deficiency after adjusting for age, sex, overweight, anemia, insulin and sulfonylurea use, DM and medication duration. The covariates selected for the multivariate regression were known or surmised factors that could influence vitamin B₁₂ status. The receiver operating characteristic (ROC) curve was used to determine the cutoff value of metformin dose and duration of metformin therapy associated with vitamin B₁₂ deficiency. The optimum cutoff value was determined based on the highest Youden index [$J = (\text{sensitivity} + \text{specificity}) - 1$]. A p value <0.05 was considered statistically significant. Data processing was done using Microsoft Excel 2016. Statistical analysis and graphical presentation were performed using the R Language for Statistical Computing version 3.5.2 (R Core Team, Vienna, Austria) [26].

3. Results

A total of 196 T2DM patients with mean age of 50.4 (± 6.8) years were included in this study. The median duration of T2DM and metformin therapy was 6.0 (3.0–10.0) years and 5.0 (3.0–8.0) years, respectively. There were more females (69.9%) than males (30.1%). The prevalence of anemia based on hemoglobin level was 45.9% and the average vitamin B₁₂ and MMA levels among the entire study population were 205.4 pg/ml and 0.07 μ mol/L, respectively (Table 1).

The prevalence of vitamin B₁₂ deficiency based on serum vitamin B₁₂ (sVB₁₂), MMA, and the combination of both methods (sVB₁₂+ MMA) were 63/196 (32.1%), 29/196 (14.8%), and 28/196 (14.3%), respectively (Figure 2).

Table 1. Baseline characteristics of entire study subjects.

Variables	Mean \pm SD
Age (years)	50.4 \pm 6.8
Sex ^a	
Male	59 (30.1)
Female	137 (69.9)
Hb (g/dL)	12.2 \pm 1.2
Anemic status ^a	90 (45.9)
Biochemical Parameters	
FPG (mmol/L) ^b	8.2 (6.5–11.8)
HbA1c (%)	7.1 \pm 1.8
TC (mmol/L)	5.2 \pm 1.3
TG (mmol/L)	1.7 \pm 0.6
HDL-C (mmol/L)	1.2 \pm 0.3
LDL-C (mmol/L)	3.7 \pm 1.2
Calcium (mmol/L)	2.4 \pm 0.2
Vitamin B ₁₂ (pg/ml) ^b	202.1(132.1–253.8)
MMA (μ mol/L) ^b	0.07(0.01–0.2)
Hemodynamic indices	
SBP(mmHg)	137.8 \pm 18.7
DBP(mmHg)	83.6 \pm 10.6
Anthropometric Indices	
BMI (kg/m ²)	28.6 \pm 5.6
WHR	0.9 \pm 0.1
WHtR	0.6 \pm 0.1
Visceral fat (%) ^b	9.5(6.0–14.0)
Body fat (%) ^b	30.3(24.9–38.0)
Skeletal muscle (%)	28.1 \pm 4.7
Duration of DM (years) ^b	6.0(3.0–10.0)
Duration of metformin therapy (years) ^b	5.0(3.0–8.0)

Parametric data are presented as mean \pm standard deviation, while non-parametric data presented as median (interquartile range), Hb: Hemoglobin level, FPG: Fasting Plasma Glucose, HbA1c: Glycated hemoglobin, TC: Total Cholesterol, TG: Triglyceride, HDL-C: High Density Lipoprotein Cholesterol, LDL-C Low Density Lipoprotein, MMA: Methylmalonic Acid, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, BMI: Body mass index, WHR: Waist-hip ratio, WHtR: waist-to-height ratio. Anemia was defined as hemoglobin level <12 g/dl for females and 13 g/dl for males.

^aPresented as n (%).

^{†b}Presented as median (interquartile range).

There were no statistically significant differences between the demographic, anthropometric, biochemical parameters and vitamin B₁₂ status (Table 2).

Vitamin B₁₂ deficient subjects presented with significantly longer duration of T2DM [10.0 (7.0–11.8) vs 5.0 (3.0–9.0); $p = 0.007$] and duration of metformin use [6.0 (4.0–11.0) vs 4.0 (3.0–7.0); $p < 0.0001$] compared to non-deficient subjects. Subjects with vitamin B₁₂ deficiency significantly used higher doses of metformin (>2000 g/day) compared to non-deficient subjects (Table 3).

In the multivariate logistic regression, after adjusting for possible confounding variables, longer duration of metformin use [5–9 years; aOR = 2.83, 95% CI (1.03–7.81), $p = 0.045$ and ≥ 10 years; aOR = 4.17, 95% CI (1.41–12.33), $p = 0.010$], higher daily dose of metformin [1000–2000 mg/day; aOR = 1.34, 95% CI (0.25–2.74), $p = 0.038$ and >2000 mg/day; aOR = 1.13, 95% CI (0.39–2.97), $p = 0.047$], and very high body fat [aOR = 2.98, 95% CI (1.47–6.05), $p = 0.020$] were significantly associated with increased odds of vitamin B₁₂ deficiency (Table 4).

For daily dose of metformin, a cutoff value of 1500 mg/day presented with a sensitivity, specificity, and AUC of 71.4%, 40.1%, and 0.54 (95% CI, 0.53–0.54), respectively, in predicting vitamin B₁₂ deficiency. Additionally, \geq six (6) years duration of




Figure 2. Prevalence of vitamin B₁₂ deficiency among the entire study population.

Table 2. Demographic, anthropometric and biochemical parameters of the study population stratified by vitamin B₁₂ status.

Variables	Vitamin B ₁₂ status*		p-value
	Deficient (n = 28)	Non-deficient (n = 168)	
Age (years)	51.6 ± 6.5	50.3 ± 6.7	0.328
Sex ^a			0.278
Male	11(18.3)	49(81.7)	
Female	17(12.5)	119(87.5)	
Hb (g/dL)	12.1 ± 1.5	12.3 ± 1.3	0.410
Anemic status ^a			0.684
Anemic	14(15.7)	75(84.3)	
Non-anemic	14(13.2)	92(86.8)	
FPG (mmol/L) ^b	8.7(5.5–12.5)	8.2(6.6–11.6)	0.219
HBA1c (%)	7.2 ± 1.3	7.1 ± 1.9	0.997
TC(mmol/L)	4.9 ± 1.0	5.3 ± 1.3	0.164
TG(mmol/L)	1.6 ± 0.5	1.8 ± 0.6	0.296
HDL-C(mmol/L)	1.1 ± 0.3	1.2 ± 0.3	0.212
LDL-C(mmol/L)	3.5 ± 1.0	3.7 ± 1.2	0.267
Calcium(mg/dL)	2.3 ± 0.5	2.4 ± 0.2	0.066
BMI (kg/m ²)	29.9 ± 6.8	28.4 ± 5.4	0.219
WHR	0.9 ± 0.1	0.9 ± 0.1	0.421
WHtR	0.6 ± 0.1	0.6 ± 0.1	0.238
Skeletal muscle (%)	27.2 ± 3.9	28.2 ± 4.8	0.210

Hb: Hemoglobin level, FPG: Fasting Plasma Glucose, HBA1c: Glycated Hemoglobin, TC: Total Cholesterol, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C Low-Density Lipoprotein. BMI: Body mass index, WHR: Waist-to-hip ratio, WHtR: Waist-to-height ratio. Data are presented as mean ± SD unless otherwise specified.

*Based on the prevalence from the combination of serum vitamin B₁₂ and MMA.

^aPresented as frequency (%)

^bPresented as median (interquartile range)

metformin therapy presented with a sensitivity, specificity, and AUC of 70.4%, 62.9%, and 0.66 (95% CI, 0.57–0.75), respectively, in predicting vitamin B₁₂ deficiency (Figure 3).

4. Discussion

This study reports a high prevalence of vitamin B₁₂ deficiency among Ghanaian T2DM on metformin.

The prevalence of vitamin B₁₂ deficiency based on serum vitamin B₁₂, MMA, and the combination of both methods was 32.1%, 14.8%, and 14.3%, respectively. Vitamin B₁₂ deficient subjects presented with significantly longer duration of T2DM, duration of metformin use and used higher metformin doses compared to non-deficient subjects. Using multivariate logistic regression models, after controlling for multiple potential covariates observed in other

Table 3. Comparison of medication information and symptoms of study participants stratified by vitamin B₁₂ status.

Variables	Vitamin B ₁₂ status		p-value
	Deficient (n = 28)	Non-deficient (n = 168)	
Duration of DM (years) ^a	10.0(7.0–11.8)	5.0(3.0–9.0)	0.007
Duration of met use (years) ^a	6.0(4.0–11.0)	4.0(3.0–7.0)	<0.0001
Metformin daily doses (mg/day)			<0.0001
<1000	4 (14.3)	99(58.9)	
1000–2000	6(21.4)	27(16.1)	
>2000	18(64.3)	42(25.0)	
Metformin +other drugs (Yes, %)	22(78.6)	107(63.7)	0.138
Sign of weakness (Yes, %)	7(25.0)	60(35.7)	0.291
Constipation (Yes, %)	4(14.3)	11(6.5)	0.239
Diarrhea(Yes, %)	1(3.6)	11(6.5)	1.000
Loss of appetite (Yes, %)	0(0.0)	12(7.1)	0.221
Sign of nerve problems (Yes, %)	16(57.1)	104(61.9)	0.607
Gait problem (Yes, %)	5(17.9)	19(11.3)	0.352
Blurred Vision (Yes, %)	16(57.1)	64(38.1)	0.066
Sign of memory loss (Yes, %)	3(10.7)	50(29.8)	0.087
Weight loss (Yes, %)	6(21.4)	64(38.1)	0.085

^aPresented as median (interquartile range).**Table 4.** Possible risk factors for vitamin B₁₂ deficiency among the study population.

Variables	Vitamin B ₁₂ deficiency	
	aOR (95% CI)	p-value
Age (per year)	4.12(0.77–21.99)	0.623
Gender (male)	1.5(0.82–2.94)	0.180
BMI (kg/m ²)	1.02(0.96–1.08)	0.464
WHR	5.68(0.17–189.2)	0.331
WHR	101.9(0.48–2160.9)	0.742
Body Fat		
Normal	1	
Low	0.82(0.33–2.06)	0.295
High (+)	2.06(0.53–7.97)	0.675
Very High (++)	2.98(1.47–6.05)	0.020
Anemia	4.12(0.77–21.99)	0.098
Medication used		
Metformin only	1	
Metformin+ Insulin	0.84(0.37–1.93)	0.608
Metformin+ Sulfonylurea	0.73(0.32–1.61)	0.434
Duration of metformin use (years)		
<5	1	
5–9	2.83(1.03–7.81)	0.045
≥10	4.17(1.41–12.33)	0.010
Metformin daily dose (mg)		
<1000	1	
1000–2000	1.34(0.25–2.74)	0.038
>2000	1.13(0.39–2.97)	0.047
Duration of DM (years)		
<5	1	
5–9	1.40(0.41–4.83)	0.591
≥10	4.02(2.06–17.57)	0.072

BMI: Body mass index, WHtR: Waist-to-height ratio, WHR: Waist-to-hip ratio, DM: Diabetes mellitus. Multivariate logistic regression model was used to identify risk factors associated with vitamin B₁₂ deficiency after adjusting for age, sex, overweight, anemia, insulin and sulfonylurea use, DM and medication duration. A p value < 0.05 was considered statistically significant (p values of significant variables in bold print).

studies, we found longer duration of metformin use (≥5 years), higher daily dose of metformin (≥1000 mg/day) and very high body fat to be significantly associated with increased risk of vitamin B₁₂ deficiency. In determining the optimal cutoff value for daily dose of metformin and duration of metformin therapy in predicting vitamin B₁₂ deficiency, we employed the ROC curve analysis. We found metformin dose of 1500 mg/day and ≥six (6) years duration of metformin therapy to be predictive of vitamin B₁₂ deficiency among the study population.

Varying prevalence rates of vitamin B₁₂ deficiency among T2DM patients on metformin have been reported

in diverse populations. Report from an early clinical observational study by Tomkin et al. [27] among Irish diabetic patients on long-term metformin therapy with concomitant dietary management indicated a prevalence of 30% for vitamin B₁₂ malabsorption. DeFronzo et al. also reported a prevalence of 29% among American T2DM patients using metformin [28]. Another study by Sparre Hermann et al. reported a 26.7% prevalence of vitamin B₁₂ deficiency in metformin-treated T2DM patients in Sweden [29]. Additionally, a study by Damião et al. [30] and Pflipsen et al. [23] found a 22.5% and 22% prevalence of B₁₂ deficiency among Brazilian and American T2DM patients using metformin. Wulffele




Figure 3. Receiver operating characteristic (ROC) curve analysis for the duration and daily dose of metformin in relation to vitamin B₁₂ deficiency.

et al. also reported a vitamin B₁₂ deficiency prevalence of about 14% among T2DM patients treated with metformin in the Netherlands [31]. Another study by Ko et al. reported a 9.5% prevalence of vitamin B₁₂ deficiency in metformin-treated T2DM patients in Korea [32]. Furthermore, a study by Reinstatler et al. among adults ≥ 50 years of age from NHANES 1999–2006 found that biochemical vitamin B₁₂ deficiency was present in 5.8% of T2DM patients using metformin and 2.4% among those not using metformin [33]. Compared to the recent studies, the alarmingly high prevalence of vitamin B₁₂ deficiency given the conservative cutoff points utilized in this study is striking. This underscores the need for apt guidelines to address how often T2DM patients on metformin should be screened for the risk of vitamin B₁₂ deficiency which would inform appropriate prescription of vitamin B₁₂ supplements. That aside, the discrepancies in prevalence rates may be attributed to disparities in the cutoff values for B₁₂ deficiency, influence of geographical variations and dietary characteristics. Though the mechanisms underpinning metformin-induced vitamin B₁₂ deficiency have not been fully elucidated, bacterial overgrowth in the small intestine due to DM, changes in the bacterial flora, alterations in small bowel motility, the inactivation of vitamin B₁₂ absorption, and the effect of calcium on cell membranes have been proposed [10,12,27,31].

Clinically, vitamin B₁₂ deficiency has been associated with macrocytic anemia, neuropathy, and mental changes [7,15,34,35]. Thus, though anemia observed in this study may have multifactorial causes, vitamin B₁₂ deficiency-associated macrocytic anemia may be the most probable [34,35]. Importantly also, the neurologic damage can present as peripheral neuropathy and may be misconstrued for diabetic

neuropathy in patients on metformin therapy [7,15]. Thus, since vitamin B₁₂-associated neuropathy is reversible, prompt detection and treatment of vitamin B₁₂ deficiency among T2DM patients on metformin is crucial to avert permanent neurological damage. Nonetheless, it is worthy of note that we did not observe significant association between the manifestations of neuropathy and anemia with vitamin B₁₂ deficiency. A possible reason for this finding may be due to the direct neuroprotective effect of metformin through its glucose-lowering effect and antihyperglycemic-independent, direct anti-neuropathic impact on neurons including inhibition of oxidative stress-related apoptotic cell death [36,37]. Studies by Ahmed et al. in South Africa and Russo et al. in Italy [38,39] also found no significant difference in the presence of neuropathy between subjects with normal vitamin B₁₂ levels and those with vitamin B₁₂ deficiency. Additionally, though classical B₁₂ deficiency is associated with clinical symptoms such as anemia and peripheral neuropathy, these symptoms are usually absent in those with only biochemical vitamin B₁₂ deficiency [33]. This may be the reason for the non-significant association between the vitamin B₁₂ deficiency and anemia observed in this study.

The association of duration of metformin use and vitamin B₁₂ deficiency found in this study is expected as similar findings have been reported by previous studies. A study by Bauman et al. found that 12 out of 14 T2DM patients presented with reduced serum total vitamin B₁₂ levels after 3 months of metformin therapy [10]. A study by Ting et al. also found increased duration of metformin use to be associated with more than two-fold increased risk of developing

vitamin B₁₂ deficiency [12]. Another study by De Jager et al. found that the absolute risk of vitamin B₁₂ deficiency after a period of 4 years was 7.2% higher in T2DM patients on the metformin [40]. A similar finding has also been reported by Wile and Toth [13], Wulffélé et al. [31], and Andrès et al. [41]. Despite the coherence with previous studies, metformin-induced vitamin B₁₂ deficiency in this study appeared to be duration of use- and dose-dependent similar to the findings of Beulens et al. [42]. Ko et al. [32] found that T2DM patients who had taken metformin >1,000 mg/day were approximately 10 times as likely to have vitamin B₁₂ deficiency as patients taking metformin ≤1,000 mg/day which is in harmony with this present study. However, Ko et al. also found that this dose (>1,000 mg/day) was associated with vitamin B₁₂ deficiency after ≥45.5 months (≈12 years) of therapy which is a longer period compared to the cutoff predictive of vitamin B₁₂ deficiency in this study (≥6 years). The longer duration of metformin use may be due to dissimilarities in the cutoff values of B₁₂ used. Ko et al. defined vitamin B₁₂ deficiency as serum levels ≤300 pg/mL while we defined vitamin B₁₂ deficiency as serum levels of both vitamin B₁₂ < 100 pg/mL and MMA ≥ 0.4 μmol/L. The higher cutoff level in their study may have allowed for the inclusion of more vitamin B₁₂ deficient subjects with longer duration of metformin therapy, which may have been missed in this study, consequently influencing risk associations. Additionally, the interaction of duration of T2DM and duration of metformin therapy may be partly involved.

Also of note is the association between vitamin B₁₂ deficiency and very high body fat. A study by Baltaci et al. [43] reported that obesity based on bioelectric fat analysis (total body fat %) was significantly associated with vitamin B₁₂ deficiency which is in harmony with our study finding. Also consistent with our finding is a study by Pinhas-Hamiel et al. [44] who reported a greater than fourfold increased risk of reduced vitamin B₁₂ status in Israeli obese compared to normal-weight children and adolescents. Though the mechanisms underpinning the influence of obesity in vitamin B₁₂ deficiency is still under investigation, proposed mechanisms include obesity-induced B₁₂ malabsorption, poor dietary content, repeated short-term restrictive diets and increased requirements frequently seen in obese people [44–46]. Clinically, however, metformin is frequently prescribed at higher doses and for longer duration among obese T2DM patients. Thus, our finding suggests that, a more frequent assessment of vitamin B₁₂ status for obese T2DM patients using metformin may have immense positive influence in abating the high prevalence rate of metformin-induced vitamin B₁₂ deficiency.

Despite interpreting our results with caution, some limitation of the study should be acknowledged. One of which is the cross-sectional design of this study which precluded the establishment of the causal relation

between metformin and vitamin B₁₂ deficiency. Thus, case-control or longitudinal studies are required to prove any causality in this association. The small sample size is also a limiting factor. Therefore, the findings may not be generalizable to the general population. The issue of external validity is also of concern because the study was conducted in a single urban center and significant disparities in prevalence rates may exist from different the regions. A follow up using a larger sample size is, thus, warranted.

5. Conclusion

It was evident from this study that vitamin B₁₂ deficiency is frequent in Ghanaian T2DM patients on metformin. The study also confirms findings from other countries that daily dose and duration of metformin are risk factors for the development vitamin B₁₂ deficiency. However, these findings should not be considered as a basis for discontinuing of the use of metformin in the treatment of T2DM because metformin has been proven to produce a better glycemic control in T2DM. Rather, there is the need for regular monitoring of vitamin B₁₂ levels especially in patients on ≥1500 mg daily dose of metformin for a duration of six or more years.

Acknowledgments

The authors would like to acknowledge the patients, management, and staff of Effia Nkwanta Regional Hospital.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Notes on contributors

Maryam Yakubu is a Clinical Laboratory Scientist at the Effia Nkwanta Regional Hospital, Ghana, with the qualification of MPhil.

Edwin Ferguson Laing is Senior Lecturer of Diabetology and Chemical Pathology at the Department of Molecular Medicine, School of Medical Sciences (SMS), Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana, with the qualification of Bsc, MB ChB, MSc, PhD, FGCP.

Paul Nsiah is Senior Lecturer of Chemical Pathology at the Chemical Pathology Department, School of Medical Sciences, University of Cape Coast (UCC), Cape Coast, Ghana, with the qualification of PhD.

Richard Anthony is the Medical Director and a physician specialist at the Effia Nkwanta Regional Hospital, Ghana.

Emmanuel Acheampong is a PhD student at School of Medical and Health Sciences, Edith Cowan University, Western Australia.

Samuel Kojo Asamoah is the Head of Laboratory Services, Effia Nkwanta Regional Hospital, Ghana.

Enoch Odame Anto is a PhD student at School of Medical and Health Sciences, Edith Cowan University, Western Australia.


Gabriel Djokoto is a senior medical laboratory scientist at Effia Nkwanta Regional hospital, Ghana.

Evans Adu Asamoah is an MPhil student at the Department of Molecular Medicine, SMS, KNUST, Kumasi, Ghana.

Eddie-Williams Owiredi is a Research Assistant at the Department of Molecular Medicine, SMS, KNUST, Kumasi, Ghana.

ORCID

Paul Nsiah  <http://orcid.org/0000-0002-9925-1015>

Evans Adu Asamoah  <http://orcid.org/0000-0001-6374-0979>

Eddie-Williams Owiredi  <http://orcid.org/0000-0003-4499-0678>

References

- [1] WHO. Diabetes cases could double in developing countries in next 30 years. Diabetes cases could double in developing countries in next 30 years; 2003.
- [2] Fondjo LA, Sakyi SA, Owiredi WK, et al. Evaluating vitamin D status in pre-and postmenopausal type 2 diabetics and its association with glucose homeostasis. *Biomed Res Int*. 2018;2018: 12.
- [3] Organization WH. Global report on diabetes. World Health Organization; 2016.
- [4] Amoah AG, Owusu SK, Adjei S. Diabetes in Ghana: a community based prevalence study in Greater Accra. *Diabetes Res Clin Pract*. 2002;56(3):197–205.
- [5] Darkwa S. Prevalence of diabetes mellitus and resources available for its management in the Cape Coast Metropolis. *ISABB J Health Environ Sci*. 2011;1(1):1–7.
- [6] Annani-Akollor ME, Addai-Mensah O, Fondjo LA, et al. Predominant complications of type 2 diabetes in Kumasi: a 4-year retrospective cross-sectional study at a teaching hospital in Ghana. *Medicina (B Aires)*. 2019;55(5): 125.
- [7] Zinman B, Gerich J, Buse J, et al. American Diabetes Association. Standards of medical care in diabetes-2010 (vol 33, pg S11, 2010). *Diabetes Care*. 2010;33(3):692–692.
- [8] Mazokopakis EE, Starakis IK. Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. *Diabetes Res Clin Pract*. 2012;97(3):359–367.
- [9] Group UPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352(9131):854–865.
- [10] Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. *Diabetes Care*. 2000;23(9):1227–1231.
- [11] Chapman L, Darling A, Brown J. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. *Diabetes Metab*. 2016;42(5):316–327.
- [12] Ting RZ-W, Szeto CC, Chan -MH-M, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. *Arch Internal Med*. 2006;166(18):1975–1979.
- [13] Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. *Diabetes Care*. 2010;33(1):156–161.
- [14] Lindenbaum J, Healton E, Savage D, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. 1988. *Nutrition*. (Burbank, Los Angeles County, Calif) 1995;11(2):181;discussion 180, 182.
- [15] Pierce SA, Chung AH, Black KK. Evaluation of vitamin B12 monitoring in a veteran population on long-term, high-dose metformin therapy. *Ann Pharmacother*. 2012;46(11):1470–1476.
- [16] Vashi P, Edwin P, Popiel B, et al. Methylmalonic acid and homocysteine as indicators of vitamin B-12 deficiency in cancer. *PloS One*. 2016;11(1):e0147843.
- [17] Green R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. *Am J Clin Nutr*. 2011;94(2):666S–672S.
- [18] Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B12 and folate. *Clin Chem*. 2000;46(8):1277–1283.
- [19] Oh R, Brown DL. Vitamin B12 deficiency. *Am Fam Physician*. 2003;67(5):979–986.
- [20] Shanti R, Potluri M. Sample size calculator. USA: Raosoft Inc. 2009.
- [21] Annani-Akollor ME, Laing EF, Osei H, et al. Prevalence of metabolic syndrome and the comparison of fasting plasma glucose and HbA1c as the glycemic criterion for MetS definition in non-diabetic population in Ghana. *Diabetol Metab Syndr*. 2019;11(1):26.
- [22] Owiredi E-W, Dontoh E, Essuman SE, et al. Demographic and lifestyle predictors of prehypertension: a cross-sectional study among apparently healthy adults in Kumasi, Ghana. *Biomed Res Int*. 2019;2019:7.
- [23] Pflipsen MC, Oh RC, Sagui A, et al. The prevalence of vitamin B12 deficiency in patients with type 2 diabetes: a cross-sectional study. *J Am Board Fam Med*. 2009;22(5):528–534.
- [24] Bailey RL, Carmel R, Green R, et al. Monitoring of vitamin B-12 nutritional status in the United States by using plasma methylmalonic acid and serum vitamin B-12. *Am J Clin Nutr*. 2011;94(2):552–561.

- [25] Addai-Mensah O, Gyamfi D, Duneeh R, et al. Determination of haematological reference ranges in healthy adults in three regions in Ghana. *Biomed Res Int*. 2019; 2019:6.
- [26] R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
- [27] Tomkin G, Hadden D, Weaver J, et al. Vitamin-B12 status of patients on long-term metformin therapy. *Br Med J*. 1971;2(5763):685–687.
- [28] DeFronzo RA, Goodman AM, Group MMS. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. *N Engl J Med*. 1995;333(9):541–549.
- [29] Sparre Hermann L, Nilsson B, Wettre S. Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study. *Br J Diabetes Vasc Dis*. 2004;4(6):401–406.
- [30] Damião CP, Rodrigues AO, Pinheiro MFM, et al. Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: a cross-sectional study. *Sao Paulo Med J*. 2016;134(6):473–479.
- [31] Wulffele M, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. *J Intern Med*. 2003;254(5):455–463.
- [32] Ko S-H, Ko S-H, Ahn Y-B, et al. Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. *J Korean Med Sci*. 2014;29(7):965–972.
- [33] Reinstatler L, Qi YP, Williamson RS, et al. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the national health and nutrition examination survey, 1999–2006. *Diabetes Care*. 2012;35(2):327–333.
- [34] Wickramasinghe S. Diagnosis of megaloblastic anaemias. *Blood Rev*. 2006;20(6):299–318.
- [35] Katsaros T, Filioussi K, Bonovas S. Should we screen diabetic patients using biguanides for megaloblastic anaemia? *Aust Fam Physician*. 2003;32(5):383.
- [36] Melemedjian OK, Asiedu MN, Tillu DV, et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. *Mol Pain*. 2011;7(1):70.
- [37] Yang W, Cai X, Wu H, et al. Associations between metformin use and vitamin B12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. *J Diabetes*. 2019; 11: 729–743.
- [38] Ahmed MA, Muntingh G, Rheeder P. Vitamin B12 deficiency in metformin-treated type-2 diabetes patients, prevalence and association with peripheral neuropathy. *BMC Pharmacol Toxicol*. 2016;17(1):44.
- [39] Russo G, Giandalia A, Romeo E, et al. Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin. *J Endocrinol Invest*. 2016;39(3):305–314.
- [40] De Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *Bmj*. 2010;340:c2181.
- [41] Andrès E, Noel E, Goichot B. Metformin-associated vitamin B12 deficiency. *Arch Internal Med*. 2002;162(19):2251–2252.
- [42] Beulens JW, Hart HE, Kuijs R, et al. Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin. *Acta Diabetol*. 2015;52(1):47–53.
- [43] Baltaci D, Kutlucan A, Turker Y, et al. Association of vitamin B12 with obesity, overweight, insulin resistance and metabolic syndrome, and body fat composition; primary care-based study. *Med Glas (Zenica)*. 2013;10(2):203–210.
- [44] Pinhas-Hamiel O, Doron-Panush N, Reichman B, et al. Obese children and adolescents: a risk group for low vitamin B12 concentration. *Arch Pediatr Adolesc Med*. 2006;160(9):933–936.
- [45] Kant AK. Reported consumption of low-nutrient-density foods by American children and adolescents: nutritional and health correlates, NHANES III, 1988 to 1994. *Arch Pediatr Adolesc Med*. 2003;157(8):789–796.
- [46] Samuelson G. Dietary habits and nutritional status in adolescents over Europe. an overview of current studies in the Nordic countries. *Eur J Clin Nutr*. 2000;54(S1):S21.